Mouse and Rat Models of Induction of Hepatic Fibrosis and Assessment of Portal Hypertension
Portal hypertension either develops due to progressive liver fibrosis or is the consequence of vascular liver diseases such as portal vein thrombosis or non-cirrhotic portal hypertension. This chapter focuses on different rodent models of liver fibrosis with portal hypertension and also in few non-cirrhotic portal hypertension models. Importantly, after the development of portal hypertension, the proper assessment of drug effects in the portal and systemic circulation should be discussed. The last part of the chapter is dedicated in these techniques to assess the in vivo hemodynamics and the ex vivo techniques of the isolated liver perfusion and vascular contractility.
Key wordsPortal hypertension Bile duct ligation Carbon tetrachloride Methionine-choline-deficient diet High-fat diet Partial portal vein ligation Colored microsphere technique Isolated in situ liver perfusion Aortic ring contraction
The Laboratory is supported by grants from the Deutsche Forschungsgemeinschaft (SFB TRR57 to P18), the H. J. & W. Hector Stiftung, Ernst-Bertha-Grimmke-Stiftung (6/15) and European Union’s Horizon 2020 research and innovation programme (No 668031).
- 5.Klein S, Herath CB, Schierwagen R et al (2015) Hemodynamic effects of the non-peptidic angiotensin-(1-7) agonist AVE0991 in liver cirrhosis. PLoS One 10(9):e0138732. doi: 10.1371/journal.pone.0138732
- 8.Uschner FE, Ranabhat G, Choi SS et al (2015) Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension. Sci Rep 5:14573. doi: 10.1038/srep14573 CrossRefPubMedPubMedCentralGoogle Scholar